

Cancer
Radiotherapy
Proton Beam Therapy Service (All Ages)

170071S(HSS)

Code	Metric	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Notes	Q1	Q2	Q3	Q4
170012/S(HSS)-19-101	Number of adults referred	Number of adults referred		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
170012/S(HSS)-19-102	Number of adults planned	Number of adults planned		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
170012/S(HSS)-19-103	Number of adults treated	Number of adults treated		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
170012/S(HSS)-19-104	Number of teenagers & young adults referred	Number of teenagers & young adults referred (age 16 to 24 years)		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
170012/S(HSS)-19-105	Number of teenagers & young adults planned	Number of teenagers & young adults planned (age 16 to 24 years)		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
170012/S(HSS)-19-106	Number of teenagers & young adults treated	Number of teenagers & young adults treated (age 16 to 24 years)		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
170012/S(HSS)-19-107	Number of children referred	Number of children referred		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
170012/S(HSS)-19-108	Number of children planned	Number of children planned		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
170012/S(HSS)-19-109	Number of children treated	Number of children treated		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
170012/S(HSS)-19-110	Mean time from decision to treat to first treatment	Mean time from decision to treat to first treatment (from 1st Outpatient appointment)		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
170012/S(HSS)-19-111	% of children who received general anaesthesia	Of those in the denominator, number of children who received general anaesthesia	Number of children treated	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23
170071S(HSS)-20-112	Five year overall survival	Five year overall survival		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
170071S(HSS)-20-113	5 year progression free	5 year progression free by diagnosis & tumour site		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
170071S(HSS)-20-114	% patients with local tumour control at 5 years	% patients with local tumour control at 5 years by diagnosis & tumour site		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
170071S(HSS)-20-115	% patients with short term effects of treatment	% patients with short term effects of treatment by diagnosis & tumour site		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
170071S(HSS)-20-116	% patients with long term effects of treatment	% patients with long term effects of treatment by diagnosis & tumour site		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
170071S(HSS)-20-117	Proportion of patients receiving the required number of fractions within the planned length of treatment	Proportion of patients receiving the required number of fractions within the planned length of treatment		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
170071S(HSS)-20-118	% of equipment uptime	% of equipment uptime		Annual	Annual	Provider				N/A	N/A	N/A	Apr-23 - Mar-23
170071S(HSS)-20-119	Number of patients receiving back up treatment,	Number of patients receiving back up treatment, i.e. alternative RT to PBT.		Annual	Annual	Provider				N/A	N/A	N/A	Apr-22 - Mar-23
170071S(HSS)-20-120	% patients entered into clinical trials	Of those in the denominator, the number of patients entered into clinical trials	Number of patients in the reporting period	Annual	Annual	Provider	Provider			N/A	N/A	N/A	Apr-22 - Mar-23